Get started
Author

Santosh Kumar Behera

Observed names: Behera Santosh Kumar, K B Santosh, Santosh Behera, Santosh K. Behera
Observed institutions: Government of India, Regional Medical Research Center, Indian Council of Medical Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research - Ahmedabad, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research
ORCID: 0000-0001-7915-187X
Observed ORCID: 0000-0001-7915-187X
OpenAlex ID: A5114859313
Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics
2021 · Ambika Chamoli, Abhishek S. Gosavi, et al. · Oral Oncology · 592
Chlorogenic Acid: a Polyphenol from Coffee Rendered Neuroprotection Against Rotenone-Induced Parkinson’s Disease by GLP-1 Secretion
2022 · Nishant Sharma, Ritu Soni, et al. · Molecular Neurobiology · 54
Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir
2021 · Santosh Kumar Behera, Nazmina Vhora, et al. · Scientific Reports · 48
PDF
Mechanistic Investigation of Thiazole-Based Pyruvate Kinase M2 Inhibitor Causing Tumor Regression in Triple-Negative Breast Cancer
2024 · Rudradip Das, Priyanka Pulugu, et al. · Journal of Medicinal Chemistry · 27
In-silico and in-vitro investigation of STAT3-PIM1 heterodimeric complex: Its mechanism and inhibition by curcumin for cancer therapeutics
2022 · Sutapa Mahata, Santosh Kumar Behera, et al. · International Journal of Biological Macromolecules · 20
Diaryl ether derivative inhibits GPX4 expression levels to induce ferroptosis in thyroid cancer cells
2023 · Deepika Pamarthy, Santosh Kumar Behera, et al. · Drug Development Research · 14
PDF
Sequence analysis of Indian SARS-CoV-2 isolates shows a stronger interaction of mutant receptor-binding domain with ACE2
2021 · Pujarini Dash, Jyotirmayee Turuk, et al. · International Journal of Infectious Diseases · 12
PDF
Biocomputational Assessment of Natural Compounds as a Potent Inhibitor to Quorum Sensors in Ralstonia solanacearum
2022 · Sunil Kumar, Khurshid Ahmad, et al. · Molecules · 11
PDF
Sublingual Delivery of Human GLP-1 Loaded Nanoliposomal Hydrogel for Treatment of Type 2 Diabetes Mellitus
2025 · Shivani Khopade, Tejas Girish Agnihotri, et al. · AAPS PharmSciTech · 10
In Silico Analysis Determining the Binding Interactions of NAD(P)H: Quinone Oxidoreductase 1 and Resveratrol via Docking and Molecular Dynamic Simulations
2023 · Santosh Behera, Christoffer Lambring, et al. · European Journal of Biology · 8
Evaluation of 1-vinyl-3-alkyl imidazolium-based ionic liquid monomers towards antibacterial activity: An in-silico & in-vitro study
2024 · Itishree Panda, Sangeeta Raut, et al. · Computational Biology and Chemistry · 7
Dendronized Polymeric Biomaterial for Loading, Stabilization, and Targeted Cytosolic Delivery of microRNA in Cancer Cells
2022 · Vishakha Tambe, Sagarkumar Patel, et al. · ACS Applied Bio Materials · 7
Scrutinizing the antibacterial activity of poly (1‐vinyl‐3‐alkyl imidazolium) ionic liquids: experimental and computational approach
2024 · Itishree Panda, Santosh Kumar Behera, et al. · Journal of Chemical Technology & Biotechnology · 6
Experimental and in silico insights: interaction of dimethyl sulphoxide with 1-hexyl-2-methyl imidazolium bromide/1-octyl-2-methyl imidazolium bromide at different temperatures
2024 · Itishree Panda, Bikash Ranjan Behera, et al. · RSC Advances · 5
PDF
Semisynthesis of Glycosmis pentaphylla Alkaloid Derivatives: Pyranoacridone-Hydroxamic Acid Cytotoxic Conjugates with HDAC and Topoisomerase II α Dual Inhibitory Activity
2025 · Parusu Kavya Teja, Bao Q. Ly, et al. · Journal of Natural Products · 4
Computational Biology of BRCA2 in Male Breast Cancer, through Prediction of Probable nsSNPs, and Hit Identification
2022 · Sangita Dattatray Shinde, Dinesh Parshuram Satpute, et al. · ACS Omega · 4
ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma
2026 · Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
PDF
In‐silico and In‐vitro Investigation of Flavonoids and Alkaloids from Artocarpus heterophyllus, Tinospora cordifolia, and Glycosmis pentaphylla as Potential NF‐κB Inhibitors in Oral Cancer
2024 · Komal Nagesh Gotsurve, Joyeeta Das, et al. · Chemistry & Biodiversity · 3
Interaction Between 2‐Methylimidazole and 1‐Butanol/1‐Octanol: Thermophysical and Computational Studies
2023 · Sanghamitra Pradhan, Santosh Kumar Behera, et al. · ChemistrySelect · 3
Pharmacoinformatics approach for type 2 diabetes mellitus therapeutics using phytocompounds from Costus genus: an in-silico investigation
2024 · Drashti Bhavsar, Suraj Kutre, et al. · Journal of Biomolecular Structure and Dynamics · 2
In silico mutation of aromatic with aliphatic amino acid residues in Clostridium perfringens epsilon toxin (ETX) reduces its binding efficiency to Caprine Myelin and lymphocyte (MAL) protein receptors
2023 · Sunil Kumar, Santosh Kumar Behera, et al. · Journal of Biomolecular Structure and Dynamics · 2
Correction: Chlorogenic Acid: a Polyphenol from Coffee Rendered Neuroprotection Against Rotenone-Induced Parkinson’s Disease by GLP-1 Secretion
2022 · Nishant Sharma, Ritu Soni, et al. · Molecular Neurobiology · 2
PDF
Exploring curcumin and its synthetic derivatives against key genes for therapeutics of rheumatoid arthritis in the Indian population: a computational approach
2026 · Arushi Saloki, Jayshri Swarnkar, et al. · In Silico Pharmacology · 1
In silico investigation of human GLP-1 for diabetic nephropathy and in-vitro and in-vivo evaluation of its formulation
2025 · Shraddha Baviskar, Tejas Girish Agnihotri, et al. · Biochemical and Biophysical Research Communications · 1
Checkpoint Genes in Check: Impact of BUB1, BUB1B, and MAD2 Alterations on the Treatment Outcomes of Advanced Ovarian Cancer
2025 · Sinjini Sarkar, Ranita Pal, et al. · Journal of Current Oncological Trends · 1
Works count: 51
Citation count: 848
H-index: 9
I10-index: 9
Year
Topic
Type